Bicalutamide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
<scene name='10/1022391/Cv/4'>Androgen Receptor Ligand-binding Domain W741L Mutant Complex with R-bicalutamide</scene> ([[1z95]]). | <scene name='10/1022391/Cv/4'>Androgen Receptor Ligand-binding Domain W741L Mutant Complex with R-bicalutamide</scene> ([[1z95]]). | ||
<scene name='10/1022391/Cv/6'>Bicalutamide binding site</scene>. | |||
Although bicalutamide has been patented since 1982 and approved to be clinical used by the FDA since 1995 <ref name="bicalutamide" />, its mechanism of action is still under debate. The X-ray structure of the wild-type AR bound to an antagonist is not yet solved <ref name="MoA" />. Changes in the conformation of the receptor, due to association with antagonists, have been hypothesized to be similar to those produced in the steroid receptor family <ref name="ARA prostate" /><ref name="MoA" />. | Although bicalutamide has been patented since 1982 and approved to be clinical used by the FDA since 1995 <ref name="bicalutamide" />, its mechanism of action is still under debate. The X-ray structure of the wild-type AR bound to an antagonist is not yet solved <ref name="MoA" />. Changes in the conformation of the receptor, due to association with antagonists, have been hypothesized to be similar to those produced in the steroid receptor family <ref name="ARA prostate" /><ref name="MoA" />. | ||